



Transparency notification UCB SA/NV

- **Notification referring to situation on 8 March 2019**
- **Threshold crossed: 3%**
- **Latest holding: 3.07%**

Brussels (Belgium), 13 March 2019 – 20:00 (CET) – regulated information

1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has filed a transparency notification.

The transparency notification dated 12 March 2019 has been submitted in accordance with Article 18 *juncto* Article 6 of the law of 2 May 2007 on the disclosure of large shareholdings, due to the sale of options (assimilated financial instruments) and subsequent purchases of UCB shares by UCB Fipar SA to cover its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group. As a result thereof, voting rights relating to voting securities held by UCB SA/NV and its affiliates crossed the 3% threshold on 8 March 2019.

On 8 March 2019, UCB SA/NV (taking into account the holding of its affiliates) owned 5 975 516 UCB shares with voting rights (versus 5 597 184 UCB shares in its previous notification dated 7 January 2019), representing 3.07% of the total number of shares issued by the company (194 505 658) (versus 2.88% in the notification dated 7 January 2019). Assimilated financial instruments held by UCB SA/NV and its affiliates dropped to zero (versus 0.22% in the notification dated 7 January 2019).

2. Content of the notification

The transparency notification dated 12 March 2019 includes the following information:

- **Reason for the notification:**
 - Acquisition or disposal of voting securities or voting rights
 - Acquisition or disposal of financial instruments that are treated as voting securities
- **Notification by:** A parent undertaking or a controlling person.

- **Person subject to the notification requirement:**

Name	Address (for legal entities)
UCB SA/NV	Allée de la recherche 60, 1070 Brussels (Anderlecht)

- **Date on which the threshold is crossed :** 8 March 2019.
- **Threshold crossed (in %):** 3%.
- **Denominator:** 194 505 658.
- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holder of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
UCB SA/NV	2,102,356	2,025,676		1.04%	
UCB Fipar SA	3,494,828	3,949,840		2.03%	
Subtotal	5,597,184	5,975,516		3.07%	
TOTAL		5,975,516	0	3.07%	0.00%

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
UCB Fipar SA	options			0	0.00%	cash
UCB Fipar SA	options			0	0.00%	cash
TOTAL				0	0.00%	

TOTAL (A & B)	# of voting rights	% of voting rights
CALCULATE	5,975,516	3.07%

- **Chain of controlled undertakings through which the holding is effectively held:**

UCB SA/NV indirectly controls UCB Fipar SA.

- **Additional information:**

The disclosure obligation arose due to voting rights held by UCB SA and its affiliates crossing the 3% minimum threshold. The variation is due to the sale of options (assimilated financial instruments) and subsequent share purchases by UCB Fipar SA to cover its obligations towards employees in the framework of the Long Term Incentive plans of the UCB group.

3. Further information

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

Investor Relations

Antje Witte,
Investor Relations, UCB
T +32 2 559 94 14,
antje.witte@ucb.com

Isabelle Ghellynck,
Investor Relations, UCB
T +32 2 559 95 88,
isabelle.ghellynck@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7 500 people in approximately 40 countries, the company generated revenue of € 4.6 billion in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.